Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

By sjmartinez • May 19, 2025

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385. Epub ahead of print. PMID: 40384092.

Tags: Anti-CTLA-4, anti-PD-L1, Cedars Sinai DoM, Hematology/Oncology, immune checkpoint inhibitors, Publications, safety, survival

How I do it: Best practices for right heart catheterization in the diagnosis of pulmonary hypertension

Matusov Y, Kolaitis NA, Geft D, DesJardin J, Barnett C, Hage A, De Marco T, Lewis MI. How I do it: Best practices for right[...]

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement

Oprea AD, Ostapenko LJ, Sweitzer B, Selzer A, Irizarry-Alvarado JM, Hurtado Andrade MD, Mendez CE, Kelley KD, Stewart E, Fernandez Robles CR, Chadha RM, Camilleri[...]

Recommendations to Overcome Barriers to Transplant Fellowship Training: A Report from the American Society of Transplantation Fellows Task Force

Kobashigawa J, Levitsky J, Singh N, Khush K, Pinney S, Aby E, Afzal A, Adey D, Bhalla A, Doshi M, Farouk S, Fox A, Hall[...]